Immunome (NASDAQ:IMNM) Given Outperform Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Immunome (NASDAQ:IMNM) in a research note released on Thursday morning,RTT News reports. Wedbush currently has a $21.00 price target on the stock.

IMNM has been the subject of a number of other reports. Craig Hallum began coverage on Immunome in a research note on Friday, September 5th. They issued a “buy” rating and a $26.00 target price for the company. Evercore ISI began coverage on shares of Immunome in a research note on Friday, August 22nd. They issued an “outperform” rating and a $18.00 price objective for the company. Guggenheim reiterated a “buy” rating and set a $25.00 target price on shares of Immunome in a research report on Monday, August 25th. JPMorgan Chase & Co. lowered their target price on shares of Immunome from $23.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of Immunome from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Nine investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $22.89.

Immunome Stock Performance

Shares of IMNM opened at $9.85 on Thursday. The company has a 50-day simple moving average of $9.99 and a 200-day simple moving average of $8.84. Immunome has a 52 week low of $5.15 and a 52 week high of $16.55. The firm has a market capitalization of $857.34 million, a P/E ratio of -3.20 and a beta of 1.92.

Immunome (NASDAQ:IMNM) last released its earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.02. The business had revenue of $4.02 million for the quarter, compared to the consensus estimate of $1.03 million. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%. As a group, equities analysts forecast that Immunome will post -2.21 earnings per share for the current year.

Institutional Trading of Immunome

Hedge funds and other institutional investors have recently modified their holdings of the stock. Teacher Retirement System of Texas boosted its stake in Immunome by 6.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock worth $172,000 after acquiring an additional 1,188 shares during the last quarter. Main Management ETF Advisors LLC raised its holdings in Immunome by 1.6% in the second quarter. Main Management ETF Advisors LLC now owns 76,944 shares of the company’s stock worth $716,000 after purchasing an additional 1,248 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in shares of Immunome by 3.2% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 53,187 shares of the company’s stock worth $470,000 after purchasing an additional 1,643 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Immunome by 6.4% in the 1st quarter. Invesco Ltd. now owns 28,379 shares of the company’s stock valued at $191,000 after buying an additional 1,718 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after buying an additional 2,909 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.